Literature DB >> 9660193

Changes in glycosaminoglycan structure and composition of the main heparan sulphate proteoglycan from human colon carcinoma cells (perlecan) during cell differentiation.

A Molist1, M Romarís, U Lindahl, J Villena, M Touab, A Bassols.   

Abstract

Colon carcinoma cells provide a useful model to study the biochemical processes associated with cell differentiation. Undifferentiated HT29, differentiated HT29MTX(-3) and HT29MTX(-6), and Caco2 human colon carcinoma cells have been used to study the production of proteoglycans and to characterize the glycosaminoglycan structure of the heparan sulphate chains. All the cell lines produce mainly a heparan sulphate proteoglycan that is found partly in the extracellular medium and associated to the cell membrane. The heparan sulphate proteoglycans from the media were purified by ion-exchange chromatography and subjected to structural analysis. The heparan sulphate proteoglycan from differentiated cells is larger and more homogeneous in size than the heparan sulphate proteoglycan from undifferentiated HT29 cells. No differences in protein core structure were observed when cells were labeled with [35S]methionine and the protein cores visualized by gel electrophoresis. Nevertheless, differences in glycosaminoglycan composition were found correlated with the degree of differentiation. The heparan sulphate chains from differentiated HT29MTX(-3) and HT29MTX(-6) cells have a higher sulphation degree than those from undifferentiated HT29 cells. The heparan sulphate from Caco2 cells is the most highly sulphated species. The differences are mainly attributed to O-sulphate groups. The increase in O-sulphation was more pronounced for D-glucosamine 6-O-sulphate than for L-iduronic acid 2-O-sulphate groups.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9660193     DOI: 10.1046/j.1432-1327.1998.2540371.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  10 in total

1.  Mechanistic studies on nonviral gene delivery to the intestine using in vitro differentiated cell culture models and an in vivo rat intestinal loop.

Authors:  Sally-Ann Cryan; Caitriona M O'Driscoll
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

2.  Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria.

Authors:  Elizabeth Furrie; Sandra Macfarlane; George Thomson; George T Macfarlane
Journal:  Immunology       Date:  2005-08       Impact factor: 7.397

Review 3.  Role of heparan sulfate in ocular diseases.

Authors:  Paul J Park; Deepak Shukla
Journal:  Exp Eye Res       Date:  2013-02-11       Impact factor: 3.467

Review 4.  Disease-modifying therapies for osteoarthritis : current status.

Authors:  Marc Fajardo; Paul E Di Cesare
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

5.  The human D-glucuronyl C5-epimerase gene is transcriptionally activated through the beta-catenin-TCF4 pathway.

Authors:  Giancarlo Ghiselli; Amit Agrawal
Journal:  Biochem J       Date:  2005-09-01       Impact factor: 3.857

6.  Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding.

Authors:  Gerdy B ten Dam; Els M A van de Westerlo; Anurag Purushothaman; Radu V Stan; Johan Bulten; Fred C G J Sweep; Leon F Massuger; Kazuyuki Sugahara; Toin H van Kuppevelt
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

Review 7.  Perlecan and tumor angiogenesis.

Authors:  Xinnong Jiang; John R Couchman
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

8.  Changes in composition and sulfation patterns of glycoaminoglycans in renal cell carcinoma.

Authors:  Ebru Ucakturk; Orkun Akman; Xiaojun Sun; Dilek Ertoy Baydar; Anil Dolgun; Fuming Zhang; Robert J Linhardt
Journal:  Glycoconj J       Date:  2015-12-14       Impact factor: 2.916

9.  The stoichiometry of peptide-heparan sulfate binding as a determinant of uptake efficiency of cell-penetrating peptides.

Authors:  Rike Wallbrecher; Wouter P R Verdurmen; Samuel Schmidt; Petra H Bovee-Geurts; Felix Broecker; Anika Reinhardt; Toin H van Kuppevelt; Peter H Seeberger; Roland Brock
Journal:  Cell Mol Life Sci       Date:  2013-11-24       Impact factor: 9.261

10.  The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells.

Authors:  Bodil Fadnes; Oystein Rekdal; Lars Uhlin-Hansen
Journal:  BMC Cancer       Date:  2009-06-15       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.